PRESS RELEASE

DIASORIN, IN PARTNERSHIP WITH QIAGEN, UNVEILS THE NEXT GENERATION OF THE LIAISON QUANTIFERON-TB GOLD PLUS II ASSAY TO DELIVER SIGNIFICANT TESTING PRODUCTIVITY AND FASTER RESULTS IN ALL COUNTRIES ACCEPTING THE CE MARK

THE NEW LIAISON QUANTIFERON-TB GOLD PLUS II ASSAY:

- IS A FULLY AUTOMATED CHEMILUMINESCENT IMMUNOASSAY (CLIA) SOLUTION FOR THE DETECTION OF *M. TUBERCULOSIS* INFECTIONS;
- DELIVERS THE NEXT AUTOMATED IGRA TESTING FOR THE DETECTION OF *M. TUBERCULOSIS* INFECTIONS WITH 25% FASTER TURNAROUND TIME;
- ENABLES TESTING OF APPROXIMATELY 75% MORE PATIENTS PER HOUR COMPARED TO THE PREVIOUS FULLY AUTOMATED CHEMILUMINESCENT IMMUNOASSAY (CLIA) SOLUTION;
- OPTIMIZES LABORATORY WORKFLOW FOR MAXIMUM EFFICIENCY AND THROUGHPUT.

Saluggia, Italy – Venlo, the Netherlands – November 18, 2025 - Diasorin (FTSE MIB: DIA) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the CE-marked launch of the new LIAISON QuantiFERON-TB Gold Plus II, a next-generation assay that redefines speed and throughput as an aid in the diagnosis of *M. tuberculosis* infection on LIAISON analyzer systems.

The new assay enables laboratories to test up to 75% more patients per hour and achieve a 25% faster turnaround time compared to the previous version. This marks a major advance in workflow efficiency and productivity for TB diagnostics, combining QIAGEN's gold-standard QuantiFERON technology with Diasorin's high-throughput LIAISON platforms — giving laboratories a faster, more efficient solution to meet growing global demand for TB testing.

Latent tuberculosis infection (LTBI) affects roughly 25% of the world's population, with up to 10% at risk of progressing to active disease if untreated. Faster, scalable testing is essential to achieving World Health Organization (WHO) targets for TB elimination. The new LIAISON QuantiFERON-TB Gold Plus II provides laboratories with a powerful tool to expand screening access and strengthen global TB prevention efforts.

"With the new LIAISON QuantiFERON-TB Gold Plus II, we are equipping laboratories with a powerful, high-throughput tool to meet growing global demand for TB testing", commented Chen Even, PhD, Chief Commercial Officer of Diasorin. *"This next-generation solution optimizes the world's leading latent TB test for automated, high-volume environments. It enables labs to screen more at-risk patients efficiently, helping prevent progression to active TB and advancing global TB control initiatives."*

Diasorin and QIAGEN have worked together since 2017 to integrate QuantiFERON technology into the LIAISON family of analyzers, combining QIAGEN's diagnostic leadership with Diasorin's automation expertise. Today, more than 7,000 LIAISON systems are installed globally, enabling high-volume testing labs to process QuantiFERON-TB Gold Plus II with minimal hands-on time, full traceability and seamless IT integration.

PRESS RELEASE

"We are very pleased about our partnership with QIAGEN which brings to market a unique solution to address one of the diseases identified by the World Health Organization as a major clinical challenge", commented Carlo Rosa, Chief Executive Officer of Diasorin. *"This next-generation tuberculosis assay is a clear demonstration that by joining forces, Diasorin and QIAGEN can continuously expand their market presence - particularly in laboratories transitioning from skin-based to blood-based testing - by leveraging robust, proven technologies and platforms."*

"The new LIAISON QuantiFERON-TB Gold Plus II marks another milestone in our mission to help end tuberculosis," said Thierry Bernard, Chief Executive Officer of QIAGEN. *"Through our close collaboration with Diasorin, this is an important step in driving the fifth generation of QuantiFERON technology and expanding access to accurate, automated TB testing designed to support global efforts to eliminate this devastating disease."*

About Diasorin

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 31 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

DIASORIN CONTACTS:

INVESTOR RELATIONS

Riccardo Fava
Corporate VP Communication, ESG & Investor Relations
riccardo.fava@diasorin.com

Eugenia Ragazzo
Corporate Investor Relations & ESG Senior Analyst
eugenia.ragazzo@diasorin.com

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of June 30, 2025, QIAGEN employed approximately 5,700 people in over 35 locations worldwide. For more information, visit www.qiagen.com.

QIAGEN CONTACTS:

INVESTOR RELATIONS
e-mail: ir@QIAGEN.com

PUBLIC RELATIONS
e-mail: pr@QIAGEN.com